Non-fused thiophene derivatives and their uses
AssigneeEnyo Pharma
InventorsERIC MELDRUM, BENOÎT DE CHASSEY, PETER MACHIN, KARINE FABIENNE MALAGU, PAUL COLIN MICHAEL WINSHIP, MARK CHAMBERS, JAMIE DAVID KNIGHT, ROBERTA LANARO
Life of this patent
Estimating the term…
Abstract
The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
Claims15
1-15. (canceled)
A compound of formula (I):
- wherein:
- R1 represents:
- a hydrogen,
- a 3-10 membered ring, saturated or unsaturated selected from the group consisting of an aryl, a cycloalkyl, a heterocycloalkyl, a fused arylheterocycloalkyl, a fused heteroarylcycloalkyl, a fused bicycloalkyl, and a bridged carbocyclyl, said 3-10 membered ring is optionally substituted by at least one radical selected from the group consisting of:
- a halogen,
- a (C1-C6)alkyl or a (C1-C6)alkyloxy, optionally substituted by at least one halogen,
- a hydroxy,
- a —CO—R6 or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl, and
- an optionally substituted aryl, or
- a (C1-C6)alkyl, optionally substituted by at least one radical selected from the group consisting of:
- a halogen,
- a (C1-C6)alkyloxy optionally substituted by at least one halogen, and
- a 3-10 membered ring as defined above;
- R2 represents:
- a hydrogen,
- a halogen,
- a (C1-C6)alkyl optionally substituted by at least one halogen,
- an optionally substituted aryl, or
- an optionally substituted cycloalkyl;
- R3 represents:
- a 5-10 membered ring, saturated or unsaturated selected from the group consisting of:
- an aryl optionally fused to a heterocycloalkyl
- a heteroaryl,
- a cycloalkyl,
- a heterocycloalkyl, and
- a 5-10 membered bridged carbocyclyl or heterocyclyl,
- said 5-10 membered ring is optionally substituted by at least one radical selected from the group consisting of:
- a halogen,
- a (C1-C6)alkyl optionally substituted by at least one halogen, or by an optionally bridged heterocycloalkyl optionally substituted by a (C1-C6)alkyl,
- a —NH—(C1-C6)alkyl or a —N—((C1-C6)alkyl)2, optionally substituted by at least one radical selected from the group consisting of a heterocycloalkyl, a cycloalkyl, a hydroxyl, a thiacycloalkyl-1,1dioxide and a (C1-C6)alkyloxy,
- a —NH-heterocycloalkyl, a —NH-cycloalkyl, a —N((C1-C6)alkyl)-heterocycloalkyl, or a —NH((C1-C6)alkyl)-thiacycloalkyl-1,1dioxide, optionally substituted by a hydroxyl, a (C1-C6)alkyl, a (C1-C6)alkyloxy or a —CO—R6 with R6 being a hydrogen or a (C1-C6)alkyl,
- a hydroxy, a —CN, a —CO—R6 or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl,
- a (C1-C6)alkyloxy optionally substituted by at least one radical selected from the group consisting of a halogen, a hydroxy, a (C1-C6)alkyloxy, a —NR7R8 with R7 and R8 are independently a hydrogen or a (C1-C6)alkyl, a —NHCOR9, a —NHCO2R9, with R9 being a (C1-C6)alkyl, a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl, and a heterocycle,
- a —NHCOR9, a —NHCO2R9, or a —SO2R9, with R9 being a (C1-C6)alkyl, and
- a heterocycloalkyl, a bridged heterocycloalkyl, a heterocycloalkyloxy, a cycloalkyloxy, a thiaheterocycloalkyl-1,1-dioxide or a spiroheterocycloalkyl, optionally substituted by a (C1-C6)alkyl, a (C1-C6)alkyloxy, a hydroxy, a ketone, a halogen or a (C1-C6)alkyl optionally substituted by a (C1-C6)alkyloxy, or
- a (C1-C6)alkyl or a (C2-C6)alkenyl, optionally substituted by a 5-10 membered ring as defined above or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl;
- R4 represents —COOH;
- and
- R5 represents:
- a hydrogen, or
- a (C1-C6)alkyl optionally substituted by at least one halogen;
- with the proviso that when R1 is a phenyl or a phenyl substituted by a bromine, a methyl, a methoxy or an ethoxy, then R3 is not a phenyl substituted by a tert-butyl;
- and
- with the proviso that when R1 is a hydrogen, then R3 is a 5-10 membered ring and R2 is an optionally substituted aryl or an optionally substituted cycloalkyl;
- and the stereoisomers and the pharmaceutical salts thereof.
A method for treating a disease selected from the group consisting of an infection, a viral infection or a bacterial infection, a cancer, a metabolic disease, a cardiovascular disease, an inflammatory disorder, and iron storage disease or disorder comprising administering in a subject in need thereof a compound having the formula (I):
- wherein:
- R1 represents:
- a 3-10 membered ring, saturated or unsaturated selected from the group consisting of an aryl, a cycloalkyl, a heterocycloalkyl, a fused arylheterocycloalkyl, a fused heteroarylcycloalkyl, a fused bicycloalkyl, and a bridged carbocyclyl, said 3-10 membered ring is optionally substituted by at least one radical selected from the group consisting of:
- a halogen,
- a (C1-C6)alkyl or a (C1-C6)alkyloxy, optionally substituted by at least one halogen, and
- a hydroxy,
- a —CO—R6 or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl, and
- an optionally substituted aryl, and
- a (C1-C6)alkyl, optionally substituted by at least one radical selected from the group consisting of:
- a halogen,
- a (C1-C6)alkyloxy optionally substituted by at least one halogen, and
- a 3-10 membered ring as defined above, or
- a hydrogen;
- R2 represents:
- a hydrogen,
- a halogen,
- a (C1-C6)alkyl optionally substituted by at least one halogen,
- an optionally substituted aryl, or
- an optionally substituted cycloalkyl;
- R3 represents:
- a 5-10 membered ring, saturated or unsaturated selected from the group consisting of:
- an aryl optionally fused to a heterocycloalkyl,
- a heteroaryl,
- a cycloalkyl,
- a heterocycloalkyl, and
- a 5-10 membered bridged carbocyclyl or heterocyclyl,
- said 5-10 membered ring is optionally substituted by at least one radical selected from the group consisting of:
- a halogen,
- a (C1-C6)alkyl optionally substituted by at least one halogen, or by an optionally bridged heterocycloalkyl optionally substituted by a (C1-C6)alkyl,
- a —NH—(C1-C6)alkyl or a —N—((C1-C6)alkyl)2, optionally substituted by at least one radical selected from the group consisting of a heterocycloalkyl, a cycloalkyl, a hydroxyl, a thiacycloalkyl-1,1dioxide and a (C1-C6)alkyloxy,
- a —NH-heterocycloalkyl, a —NH-cycloalkyl, a —N((C1-C6)alkyl)-heterocycloalkyl, or a —NH((C1-C6)alkyl)-thiacycloalkyl-1,1dioxide, optionally substituted by a hydroxyl, a (C1-C6)alkyl, a (C1-C6)alkyloxy or a —CO—R6 with R6 being a hydrogen or a (C1-C6)alkyl,
- a hydroxy, a —CN, a —CO—R6 or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl,
- a (C1-C6)alkyloxy optionally substituted by at least one radical selected from the group consisting of a halogen, a fluorine, a hydroxy, a (C1-C6)alkyloxy, a —NR7R8 with R7 and R8 are independently a hydrogen or a (C1-C6)alkyl, a —NHCOR9, a —NHCO2R9, with R9 being a (C1-C6)alkyl, a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl, and a heterocycle,
- a —NHCOR9, a —NHCO2R9, or a —SO2R9, with R9 being a (C1-C6)alkyl, and
- a heterocycloalkyl, a bridged heterocycloalkyl, a heterocycloalkyloxy, a cycloalkyloxy, a thiaheterocycloalkyl-1,1-dioxide or a spiroheterocycloalkyl, optionally substituted by a (C1-C6)alkyl, a (C1-C6)alkyloxy, a hydroxy, a ketone, a halogen or a (C1-C6)alkyl optionally substituted by a (C1-C6)alkyloxy;
- or
- a (C1-C6)alkyl or a (C2-C6)alkenyl, optionally substituted by a 5-10 membered ring as defined above or a —CO2R6 with R6 being a hydrogen or a (C1-C6)alkyl;
- R4 represents —COOH;
- and
- R5 represents:
- a hydrogen, or
- a (C1-C6)alkyl optionally substituted by at least one halogen,
- and the stereoisomers, and the pharmaceutical salts thereof.
Dependencies are inferred from the claim text.